The hospitals findings may have implications for ongoing Ozempic and Mounjaro lawsuits, in which plaintiffs allege that manufacturers failed to adequately warn about gastrointestinal and metabolic complications
The participants were followed for a total of six months
Consistent with this recommendation, the FDA also advises withholding SGLT2 inhibitors for three days [20, 21]
That observation is now opening up the drugs to clinical trials for diseases that seem less obviously related to metabolic disorders, including Alzheimers, Parkinsons, depression and even cancer
Compounded medications from FDA-registered pharmacies provide the same therapeutic effects at a fraction of the cost
Experts in the field have flagged these concerns, too